To: | TESSERA THERAPEUTICS, INC. (cxltrademarks@wolfgreenfield.com) |
Subject: | U.S. Trademark Application Serial No. 88642455 - TESSERA - F08172000300 |
Sent: | April 28, 2020 12:59:39 PM |
Sent As: | ecom127@uspto.gov |
Attachments: |
United States Patent and Trademark Office (USPTO)
Office Action (Official Letter) About Applicant’s Trademark Application
U.S. Application Serial No. 88642455
Mark: TESSERA
|
|
Correspondence Address: |
|
Applicant: TESSERA THERAPEUTICS, INC.
|
|
Reference/Docket No. F08172000300
Correspondence Email Address: |
|
EXAMINER’S AMENDMENT
Issue date: April 28, 2020
USPTO database searched; no conflicting marks found. The trademark examining attorney searched the USPTO database of registered and pending marks and found no conflicting marks that would bar registration under Trademark Act Section 2(d). 15 U.S.C. §1052(d); TMEP §704.02.
Application has been amended as shown below. As agreed to by Christina M. Licursi on April 24, 2020, the examining attorney has amended the application as shown below. Please notify the examining attorney immediately of any objections. TMEP §707. Otherwise, no response is required. Id. In addition, applicant is advised that amendments to the goods and/or services are permitted only if they clarify or limit them; amendments that add to or broaden the scope of the goods and/or services are not permitted. 37 C.F.R. §2.71(a).
The identification of goods is amended to read as follows:
International Class 1: “Chemical and biological agents for scientific and research use, namely, for manipulating or modifying DNA; technology for enabling the engineering and modification of DNA, namely, molecular and cellular biology reagents and assays for the modification of cells and DNA”
International Class 5: “Pharmaceutical preparations and therapeutic agents, namely, for gene therapy and DNA editing; pharmaceutical and biological preparations based on gene, genome, and cellular editing, modulation, and modification for use in human therapeutics; pharmaceutical preparations, namely, therapeutic pharmaceuticals developed through genome modifications for the prevention and treatment of genomic disorders”
See TMEP §§1402.01, 1402.01(e).
/Megan Mischler/
Trademark Examining Attorney
Law Office 127
(571) 272-9997
megan.mischler@uspto.gov